Failure to Disclose Tumor Family History Leads to Insurance Denial; Court Rules: Policyholder Awarded 500,000 Compensation

After three years of coverage, Ms. Huang was diagnosed with lung cancer, but the insurance company refused to pay claiming she “failed to disclose family history of tumors.” This is the recent dilemma faced by Ms. Huang, born in the 90s, during her critical illness insurance claim process.

According to the 21st Century Business Herald, this health insurance contract dispute was recently publicly heard at the Beijing Financial Court’s Financial Street Circuit Court. The court announced on the spot: since the insurance company did not ask clear and effective questions about “family tumor history,” the policyholder did not violate the obligation of truthful disclosure, and the first-instance judgment was upheld. The insurance company is required to pay Ms. Huang 500,000 yuan in claims, refund the 6,454 yuan in premiums already paid, and waive future premiums.

This case not only concerns the personal rights of consumers but also involves the core issue of the “obligation of truthful disclosure” in insurance law.

Judge Hao Di, the presiding judge and deputy head of the Beijing Financial Court’s Filing Division, stated that statistics show nearly 70% of personal insurance disputes involve the determination of the obligation of truthful disclosure. As internet technology deeply integrates into the insurance industry, the processes of underwriting, claims, and policy issuance have become more complex, posing new challenges for the recognition of the obligation of truthful disclosure. The Beijing Financial Court uses circuit court trials and exemplary rulings to guide insurance companies to standardize their practices in underwriting, claims, and policy issuance, promoting the sustained and healthy development of the insurance industry.

Dispute Focus: Is family tumor history considered a “hereditary disease”?

The timeline goes back to August 2022, when Ms. Huang, born in the 90s, purchased a critical illness insurance policy with a coverage of 500,000 yuan, which stipulated that premiums would be waived upon diagnosis of a critical illness. In January 2025, Ms. Huang was diagnosed with lung adenocarcinoma and applied for a claim.

However, the insurance company refused to pay, citing that Ms. Huang did not truthfully disclose her “family tumor history” at the time of application. The insurer claimed that Ms. Huang’s mother had breast and ovarian cancers, and her grandmother had lung cancer. Ms. Huang was aware of her significant genetic risk for tumors but did not disclose it when applying, allegedly acting intentionally.

Ms. Huang argued that she had truthfully disclosed her relatives’ illnesses through the sales personnel at the time of application, and the insurer did not explicitly inquire about “family tumor history.” Both sides held different views, leading Ms. Huang to sue the insurance company.

The first-instance court held that since the insurer did not ask effective questions about “family tumor history,” Ms. Huang did not violate her duty of truthful disclosure. The court ordered the insurer to pay 500,000 yuan in insurance benefits, refund the 6,454 yuan in premiums paid, and waive future premiums, keeping the contract valid. The insurer appealed to the Beijing Financial Court.

Second Instance: Vague Inquiry, No Active Disclosure Obligation for the Policyholder

In the second-instance hearing, the panel focused on two main issues: first, whether the insurer’s question about “hereditary diseases” in the application form was equivalent to an effective inquiry about “family tumor history”; second, whether the sales personnel Ms. Huang contacted were insurance agents or brokers, and whether their disclosures fulfilled the obligation of truthful disclosure.

In health insurance products, insurers typically assess risk through health questionnaires in the application form. If consumers do not disclose important health information truthfully, insurers can terminate the contract or deny claims under Article 16 of the Insurance Law. However, the key point is that the policyholder’s duty of disclosure only applies to matters explicitly asked by the insurer.

The Beijing Financial Court found that, according to the Insurance Law and relevant judicial interpretations, the scope of the policyholder’s duty of truthful disclosure is limited to matters explicitly inquired about by the insurer.

In this case, the insurer’s “Personal Insurance Electronic Application Form” asked whether “the insured currently suffers from or has previously suffered from hereditary diseases,” but did not directly ask about “family tumor history.” Moreover, the definition of “hereditary diseases” in the contract did not include any mention of family tumor history.

The court pointed out that, from both a medical and a general consumer perspective, “family tumor history” cannot be equated with “hereditary disease.” Therefore, the insurer’s question was not clear or effective.

Regarding the role of the sales personnel, the court found that Ms. Huang contacted an insurance broker, not an agent of the insurance company. However, according to the “Measures for the Administration of Insurance Sales Behavior,” insurance brokers are also considered insurance sales personnel. If the insurance company authorized the broker to ask questions, Ms. Huang’s act of truthfully disclosing her relatives’ illnesses to the broker should be legally equivalent to disclosure to the insurer. Since the broker did not further inquire or refuse the application, Ms. Huang’s duty of truthful disclosure was fulfilled.

The Beijing Financial Court ultimately ruled: the appeal is dismissed, and the original judgment is upheld. This is a final ruling.

Legal Explanation: Clear inquiry is a prerequisite; policyholders’ obligations cannot be overly broad

Judge Hao Di emphasized that nearly 70% of personal insurance cases involve the recognition of the policyholder’s duty of truthful disclosure, which significantly impacts insurers and insured persons. As internet technology deepens integration into the insurance industry, the complexity of underwriting, claims, and policy issuance increases, bringing new challenges to the recognition of the duty of truthful disclosure.

He stressed that under China’s “question-and-disclose” model, insurance companies should make inquiries that are reasonable, clear, and explicit. When using professional terminology, insurers should provide explanations and avoid arbitrary broadening of inquiry scope or ambiguous language. If the questions are vague or contain ambiguous or overly broad terms, the principle of interpretive favor should be applied to ensure substantive fairness.

He pointed out that in this case, the insurer did not explicitly inquire about family tumor history, and from a medical standpoint, it is difficult to consider tumor family history as a hereditary disease. Moreover, the consumer did not conceal her mother’s illness. Demanding that consumers proactively disclose information beyond the explicit questions violates the principle of good faith and is not conducive to protecting financial consumers or the healthy development of the industry. This case, through circuit court trials and exemplary rulings, aims to guide insurance companies to standardize their practices and promote the industry’s sustained healthy growth.

Regulatory Department: Strengthen regulation of sales processes

Such disputes are not isolated in the current insurance market.

Industry insiders point out that health insurance underwriting heavily relies on the disclosure of health information, but ordinary consumers often misunderstand medical and insurance terminology, leading to information asymmetry during application.

Meanwhile, with the rapid development of internet insurance and online applications, the application process has become increasingly electronic and automated. Consumers fill out health questionnaires via mobile phones or online platforms, but vague questions or lack of explanations can trigger disputes during claims.

The Beijing Chaoyang People’s Court released the “White Paper on the Trial of Personal Insurance Contract Disputes (2020–2024)” in May 2025, which shows that during the application stage, insurers often have issues such as non-prominent prompts, inadequate explanations, and non-specific health inquiries; policyholders often do not fully fulfill their duty of truthful disclosure or underestimate the importance of health questions.

Regulatory authorities have also been strengthening supervision over insurance sales.

For example, the “Measures for the Administration of Insurance Sales Behavior,” which took effect on March 1, 2024, comprehensively regulate insurance sales activities from the source to better protect consumers’ rights.

A relevant official from the China Banking and Insurance Regulatory Commission stated that insurance sales directly impact consumers’ rights and interests. In recent years, the regulator has received numerous complaints about sales misconduct. The “Measures” clarify who can sell insurance, how to sell, and the obligations of insurers and consumers during the sales process.